Mazor Surgical Technologies Ltd. (TASE:MZOR) has obtained US Food and Drug Administration (FDA) approval for the company’s combined spinal surgical system comprising the SpineAssist miniature robotic navigation system and C-Insight 3D imaging system.
Mazor believes that the synergy that can be achieved by use of the combined system and the high added value it provides surgeons will boost company sales and support higher prices. The company will begin marketing the combined system in early 2011.
The combined system enables imaging during surgery without the need to move the patient to a CT scanning room, which will minimize the need for repeat surgical procedures on the spine. The system enables surgeons to precisely position surgical implants, based on prior planning that relies on the 3D scans.
Mazor’s share price rose 6.2% in early trading to NIS 9.52, giving a market cap of NIS 185 million.